Conmed Corp (CNMD)

$71.76

+1.64

(+2.34%)▲

Market is closed - opens 7 PM, 06 May 2024

Insights on Conmed Corp

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 327.04M → 312.27M (in $), with an average decrease of 4.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 33.07M → 19.70M (in $), with an average decrease of 40.4% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 41.3% return, outperforming this stock by 84.1%

Performance

  • $70.01
    $71.83
    $71.76
    downward going graph

    2.44%

    Downside

    Day's Volatility :2.53%

    Upside

    0.1%

    downward going graph
  • $61.05
    $137.65
    $71.76
    downward going graph

    14.92%

    Downside

    52 Weeks Volatility :55.65%

    Upside

    47.87%

    downward going graph

Returns

PeriodConmed CorpSector (Health Care)Index (Russel 2000)
3 Months
-13.96%
-2.2%
0.0%
6 Months
-30.01%
9.8%
0.0%
1 Year
-41.53%
5.4%
0.5%
3 Years
-48.17%
14.3%
-21.1%

Highlights

Market Capitalization
2.0B
Book Value
$27.12
Dividend Share
0.8
Dividend Yield
1.29%
Earnings Per Share (EPS)
2.61
PE Ratio
25.2
PEG Ratio
5.29
Wall Street Target Price
94.86
Profit Margin
6.53%
Operating Margin TTM
11.71%
Return On Assets TTM
3.47%
Return On Equity TTM
8.16%
Revenue TTM
1.3B
Revenue Per Share TTM
41.05
Quarterly Revenue Growth YOY
5.7%
Gross Profit TTM
575.7M
EBITDA
219.1M
Diluted Eps TTM
2.61
Quarterly Earnings Growth YOY
9.57
EPS Estimate Current Year
4.29
EPS Estimate Next Year
5.5
EPS Estimate Current Quarter
0.74
EPS Estimate Next Quarter
0.97

Analyst Recommendation

Buy
    71%Buy
    28%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Conmed Corp(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
11
Hold
4
4
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 32.19%

Current $71.76
Target $94.86

Company Financials

FY18Y/Y Change
Revenue
859.6M
↑ 7.94%
Net Income
40.9M
↓ 26.37%
Net Profit Margin
4.75%
↓ 2.22%
FY19Y/Y Change
Revenue
955.1M
↑ 11.11%
Net Income
28.6M
↓ 29.95%
Net Profit Margin
3.0%
↓ 1.75%
FY20Y/Y Change
Revenue
862.5M
↓ 9.7%
Net Income
9.5M
↓ 66.75%
Net Profit Margin
1.1%
↓ 1.9%
FY21Y/Y Change
Revenue
1.0B
↑ 17.18%
Net Income
62.5M
↑ 557.16%
Net Profit Margin
6.19%
↑ 5.09%
FY22Y/Y Change
Revenue
1.0B
↑ 3.45%
Net Income
-80.6M
↓ 228.84%
Net Profit Margin
-7.71%
↓ 13.9%
FY23Y/Y Change
Revenue
1.2B
↑ 18.7%
Net Income
64.5M
↓ 179.99%
Net Profit Margin
5.19%
↑ 12.9%
Q4 FY22Q/Q Change
Revenue
250.9M
↓ 8.8%
Net Income
26.6M
↓ 42.4%
Net Profit Margin
10.6%
↓ 6.18%
Q1 FY23Q/Q Change
Revenue
295.5M
↑ 17.78%
Net Income
1.8M
↓ 93.16%
Net Profit Margin
0.62%
↓ 9.98%
Q2 FY23Q/Q Change
Revenue
317.7M
↑ 7.51%
Net Income
13.7M
↑ 654.92%
Net Profit Margin
4.32%
↑ 3.7%
Q3 FY23Q/Q Change
Revenue
304.6M
↓ 4.12%
Net Income
15.8M
↑ 15.33%
Net Profit Margin
5.2%
↑ 0.88%
Q4 FY23Q/Q Change
Revenue
327.0M
↑ 7.38%
Net Income
33.1M
↑ 108.82%
Net Profit Margin
10.11%
↑ 4.91%
Q1 FY24Q/Q Change
Revenue
312.3M
↓ 4.52%
Net Income
19.7M
↓ 40.4%
Net Profit Margin
6.31%
↓ 3.8%
FY18Y/Y Change
Total Assets
1.4B
↑ 0.82%
Total Liabilities
706.9M
↓ 2.71%
FY19Y/Y Change
Total Assets
1.8B
↑ 29.65%
Total Liabilities
1.1B
↑ 50.61%
FY20Y/Y Change
Total Assets
1.8B
↓ 1.32%
Total Liabilities
1.0B
↓ 2.07%
FY21Y/Y Change
Total Assets
1.8B
↑ 0.82%
Total Liabilities
980.6M
↓ 5.95%
FY22Y/Y Change
Total Assets
2.3B
↑ 30.1%
Total Liabilities
1.6B
↑ 58.28%
FY23Y/Y Change
Total Assets
2.3B
↑ 0.11%
Total Liabilities
1.5B
↓ 5.56%
Q4 FY22Q/Q Change
Total Assets
2.3B
↑ 0.24%
Total Liabilities
1.6B
↓ 1.5%
Q1 FY23Q/Q Change
Total Assets
2.3B
↑ 0.98%
Total Liabilities
1.6B
↑ 1.01%
Q2 FY23Q/Q Change
Total Assets
2.3B
↑ 0.11%
Total Liabilities
1.5B
↓ 1.6%
Q3 FY23Q/Q Change
Total Assets
2.3B
↑ 0.13%
Total Liabilities
1.5B
↓ 0.85%
Q4 FY23Q/Q Change
Total Assets
2.3B
↓ 1.1%
Total Liabilities
1.5B
↓ 4.16%
Q1 FY24Q/Q Change
Total Assets
2.3B
↑ 0.4%
Total Liabilities
1.5B
↓ 0.76%
FY18Y/Y Change
Operating Cash Flow
74.7M
↑ 13.93%
Investing Cash Flow
-16.5M
↓ 43.19%
Financing Cash Flow
-72.3M
↑ 107.18%
FY19Y/Y Change
Operating Cash Flow
95.1M
↑ 27.35%
Investing Cash Flow
-387.7M
↑ 2248.47%
Financing Cash Flow
300.9M
↓ 516.36%
FY20Y/Y Change
Operating Cash Flow
64.5M
↓ 32.17%
Investing Cash Flow
-13.6M
↓ 96.48%
Financing Cash Flow
-52.1M
↓ 117.3%
FY21Y/Y Change
Operating Cash Flow
111.8M
↑ 73.2%
Investing Cash Flow
-14.9M
↑ 9.0%
Financing Cash Flow
-101.5M
↑ 95.06%
FY22Y/Y Change
Operating Cash Flow
33.4M
↓ 70.15%
Investing Cash Flow
-249.5M
↑ 1578.52%
Financing Cash Flow
225.0M
↓ 321.57%
Q4 FY22Q/Q Change
Operating Cash Flow
-11.6M
↓ 144.79%
Investing Cash Flow
-6.3M
↓ 93.08%
Financing Cash Flow
11.5M
↓ 75.43%
Q1 FY23Q/Q Change
Operating Cash Flow
-3.8M
↓ 66.83%
Investing Cash Flow
-4.3M
↓ 32.67%
Financing Cash Flow
5.4M
↓ 53.54%
Q2 FY23Q/Q Change
Operating Cash Flow
26.7M
↓ 793.35%
Investing Cash Flow
-5.5M
↑ 29.97%
Financing Cash Flow
-19.8M
↓ 469.85%
Q3 FY23Q/Q Change
Operating Cash Flow
46.1M
↑ 72.94%
Investing Cash Flow
-5.4M
↓ 2.44%
Financing Cash Flow
-37.2M
↑ 88.15%

Technicals Summary

Sell

Neutral

Buy

Conmed Corp is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Conmed Corp
Conmed Corp
-8.53%
-30.01%
-41.53%
-48.17%
-48.17%
Stryker Corporation
Stryker Corporation
-6.09%
18.64%
13.94%
29.24%
71.95%
Boston Scientific Corp.
Boston Scientific Corp.
6.06%
37.95%
37.14%
69.26%
94.94%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-7.68%
27.05%
-4.24%
-7.08%
39.76%
Abbott Laboratories
Abbott Laboratories
-4.18%
11.47%
-4.51%
-10.85%
33.93%
Medtronic Plc
Medtronic Plc
-1.47%
11.26%
-9.42%
-35.83%
-9.38%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Conmed Corp
Conmed Corp
25.2
25.2
5.29
4.29
0.08
0.03
0.01
27.12
Stryker Corporation
Stryker Corporation
40.83
40.83
2.92
11.85
0.18
0.07
0.01
48.92
Boston Scientific Corp.
Boston Scientific Corp.
68.14
68.14
1.8
2.25
0.09
0.04
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
37.58
37.58
5.19
2.75
0.21
0.12
NA
11.83
Abbott Laboratories
Abbott Laboratories
33.3
33.3
5.99
4.6
0.15
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
25.52
25.52
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Conmed Corp
Conmed Corp
Buy
$2.0B
-48.17%
25.2
6.53%
Stryker Corporation
Stryker Corporation
Buy
$128.2B
71.95%
40.83
15.44%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$107.2B
94.94%
68.14
11.18%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$52.0B
39.76%
37.58
23.01%
Abbott Laboratories
Abbott Laboratories
Buy
$185.5B
33.93%
33.3
13.96%
Medtronic Plc
Medtronic Plc
Buy
$106.7B
-9.38%
25.52
13.0%

Institutional Holdings

  • BlackRock Inc

    16.34%

  • Vanguard Group Inc

    11.11%

  • Capital Research Global Investors

    8.96%

  • Earnest Partners LLC

    7.62%

  • State Street Corporation

    3.86%

  • Bank of America Corp

    3.22%

Corporate Announcements

  • Conmed Corp Dividends March,2024

    In the quarter ending March,2024. Conmed Corp has declared dividend of $0.2

    Read More

Company Information

conmed corporation is a global medical technology company that specializes in the development and sale of surgical and patient monitoring products and services that allow our physician customers to deliver high quality care and as a result, enhanced clinical outcomes for their patients. our products are technological leaders in the specialties that we serve: orthopaedics, general surgery, gynecology, gastroenterology, pulmonology, and anesthesiology. conmed's mission, and the focus of every employee around the world, is to improve the quality of health care by designing, producing and marketing innovative, high-quality products. our emphasis is on our customer’s satisfaction and on our enhanced patient outcomes. we strive to demonstrate thoughtful leadership, provide meaningful opportunities for employees, and be a responsible member of the local communities in which we conduct business. conmed is headquartered in beautiful, upstate new york (utica), and employs approximately 3500

Organization
Conmed Corp
Employees
4000
CEO
Mr. Curt R. Hartman
Industry
Health Technology

Discover More

FAQs